Glassman Wealth Services’s PDL BioPharma, Inc. PDLI Stock Holding History

Glassman Wealth Services’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-109	Closed	–	–	1768
2019 Q4	$0	Hold	109	–	–	﹤0.01%	1660
2019 Q3	$0	Buy	+109	New	+$291	﹤0.01%	1572
2019 Q2	–	Sell	-145	Closed	-$1K	–	1550
2019 Q1	$1K	Buy	+145	New	+$490	﹤0.01%	992
2018 Q1	–	Sell	-90	Closed	–	–	1044
2017 Q4	$0	Buy	+90	New	+$276	﹤0.01%	885

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Glassman Wealth Services's PDLI Position: Q1 2020 in Review

Glassman Wealth Services sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 109 shares.

Glassman Wealth Services first reported a position in PDLI in Q4 2017 and held it in 4 quarters. The position peaked at $1K in Q1 2019. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

Glassman Wealth Services reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
Glassman Wealth Services sold 109 PDL BioPharma, Inc. shares in Q1 2020.
Glassman Wealth Services first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 4 quarters.
Glassman Wealth Services's PDL BioPharma, Inc. position peaked at $1K in Q1 2019.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Glassman Wealth Services's 13F filing for Q1 2020, filed 12 May 2020.